Prescient Therapeutics Ltd
ASX:PTX
Prescient Therapeutics Ltd
Revenue
Prescient Therapeutics Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Prescient Therapeutics Ltd
ASX:PTX
|
Revenue
AU$697.9k
|
CAGR 3-Years
119%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
ASX:IMM
|
Revenue
AU$256.6k
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-24%
|
|
Mesoblast Ltd
ASX:MSB
|
Revenue
$7.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
Revenue
$14.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Revenue
AU$87.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
25%
|
CAGR 10-Years
42%
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Revenue
AU$502.5m
|
CAGR 3-Years
359%
|
CAGR 5-Years
381%
|
CAGR 10-Years
N/A
|
See Also
What is Prescient Therapeutics Ltd's Revenue?
Revenue
697.9k
AUD
Based on the financial report for Dec 31, 2023, Prescient Therapeutics Ltd's Revenue amounts to 697.9k AUD.
What is Prescient Therapeutics Ltd's Revenue growth rate?
Revenue CAGR 5Y
47%
Over the last year, the Revenue growth was 317%. The average annual Revenue growth rates for Prescient Therapeutics Ltd have been 119% over the past three years , 47% over the past five years .